Microarray-Based Prediction of Polycythemia after Exposure to High Altitudes

Area of Science:

• Genomics
• Altitude Medicine
• Immunology

Background:

• High-altitude polycythemia (HAPC) affects 5-18% of individuals in high-altitude regions.
• Currently, no effective treatments exist for HAPC, emphasizing the need for preventative strategies.
• Understanding the genetic basis of HAPC is critical for developing targeted interventions.

Purpose of the Study:

• To identify key genes and molecular pathways involved in high-altitude polycythemia (HAPC) development.
• To explore the impact of short- and long-term exposure to the Qinghai-Tibet Plateau (QTP) on adaptive immunity and HAPC pathogenesis.
• To develop a predictive model for classifying HAPC patients based on genetic markers.

Main Methods:

• Analysis of microarray datasets (GSE135109 and GSE29977) from individuals exposed to the QTP.
• Gene Set Enrichment Analysis (GSEA) to identify enriched gene sets related to HAPC.
• Development of a logistic prediction model using GeneLogit to identify HAPC-associated genes.

Main Results:

• Exposure to the QTP for 30 days led to the inhibition of the adaptive immune response.
• Genes associated with HAPC were significantly enriched in Cluster1, showing upregulation by day three of QTP exposure.
• A logistic model identified 50 genes classifying HAPC patients, with LRRC18 and HCAR3 identified as potential hub genes due to significant alterations during early QTP exposure.

Conclusions:

• Early exposure to high altitudes, specifically the QTP, impacts adaptive immunity and is associated with specific gene expression patterns relevant to HAPC.
• LRRC18 and HCAR3 are identified as potential key regulators in HAPC development.
• Transcriptomic analysis during high-altitude adaptation provides insights into HAPC pathogenesis and potential preventative targets.